Article Sidebar

PDF (Tiếng Việt)
Published: 2021-06-09
Abstract Views: 1159
Views PDF (Tiếng Việt): 1441
DOI: https://doi.org/10.52852/tcncyh.v140i4.152
Issue
Vol. 140 No. 4 (2021)
Section
Các bài báo
How to Cite
Bình, N. T., Quỳnh, T. T. N. ., Thuỷ, H. T. ., Thắm, N. T. ., & Anh, N. H. . (2021). Multi-strain and high concentrated bacillus spore probiotics support treatment of inflammatory bowel disease. Journal of Medical Research, 140(4), 220-229. https://doi.org/10.52852/tcncyh.v140i4.152

Multi-strain and high concentrated bacillus spore probiotics support treatment of inflammatory bowel disease

Nguyễn Thanh Bình, Trần Thị Như Quỳnh, Hồ Thanh Thuỷ, Nguyễn Thị Thắm, Nguyễn Hoà Anh

Main Article Content

Abstract

This human trial (single-blind, controlled sample) was aimed to evaluate the safety and therapeutic supportive effects of LiveSpoÆ Colon probiotic product containing Bacillus spores of LS-III generation at high concentration of > 3 x 109 CFU/5 mL for treatment of inflammatory bowel disease (IBD). The control group followed the hospital’s treatment regimen, meanwhile the experimental group combined using the product LiveSpoÆColon at a dose of 1 ampoule / time x three times / day for a period of 30 days. Evaluating the effects of the product based on a set of criteria evaluating symptoms were tested on days 0, 7 and 30 and the results of colonoscopy on days 0 and 30. The safety was assessed by biochemical and hematological indicators on day 30. The results showed that, the symptoms in each assessment area as well as the total severity of colitis improved at day 7, and there was a clear statistical significance difference between the experimental group (177.3 ± 14.30) higher than the control group (157.8 ± 17.53) after 30 days. Furthermore, the result of colonoscopy showed that the level of ulcerative colitis was significantly reduced. Biochemical and hematological indicators on day 30 were within the allowed limits. The data suggests that the LiveSpoÆ Colon is safe and effective in supportive treatment of IBD (including Crohn’s disease and ulcerative colitis).

Article Details

Keywords

probiotics, Bacillus spores, LiveSpo® Colon, chronic inflammatory bowel disease

References

1. Lefevre M, Racedo SM, Denayrolles M, et al. Safety assessment of Bacillus subtilis CU1 for use as a probiotic in humans. Regul Toxicol Pharmacol. 2017;83:54-65.
2. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.
3. Lee E-S, Song E-J, Nam Y-D, Lee S-Y. Probiotics in human health and disease: from nutribiotics to pharmabiotics. J Microbiol. 2018;56(11):773-782.
4. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.Am J Gastroenterol. 2009;104(2):437-443.
5. Ismaeil H, Abdo W, Amer S, et al. Ameliorative Effect of Heat-Killed Lactobacillus plantarum L. 137 and/or Aloe vera against Colitis in Mice. Processes. 2020;8(2):225.
6. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis. 2020;52(5):534-540.
7. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305-309.
8. Horosheva T V, Vodyanoy V, Sorokulova I. Efficacy of Bacillus probiotics in prevention of antibiotic-associated diarrhoea: a randomized, double-blind, placebo-controlled clinical trial. JMM Case Reports. 2014;1(3):e004036.
9. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat Genet. 2008;40(6):710-712.
10. Sokale AO, Menconi A, Mathis GF, et al. Effect of Bacillus subtilis DSM 32315 on the intestinal structural integrity and growth performance of broiler chickens under necrotic enteritis challenge. Poult Sci. 2019;98(11):5392-5400.
11. Sudha MR, Jayanthi N, Pandey DC, et al. Bacillus clausii UBBC-07 reduces severity of diarrhoea in children under 5 years of age: a double blind placebo controlled study. Benef Microbes. 2019;10(2):149-154.
12. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Astroenterology 1989; 96(3):804-810.
13. Yarlas A, Maher S, Bayliss M, et al. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev. 2020; 7(2): 189–205. 
14. Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis. 2004;10(3):261-269.
15. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders.Gastroenterology. 2006;130(5):1480-1491.